MannKind Corporation

MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas.

First, we are continuing to execute the Technosphere® Insulin clinical trial program.

Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.

Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.

http://www.mannkindcorp.com